Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate

Arthritis Research and Therapy

Volumn 15, Issue 6, 2013, Pages

  Revu, Shankar ^a   Neregård, Petra ^a   af Klint, Erik ^a   Korotkova, Marina ^a,b   Catrina, Anca I ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Actar AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL PROTEIN; COLONY STIMULATING FACTOR 1; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PREDNISOLONE; IMMUNOSUPPRESSIVE AGENT; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ADULT; AGED; ARTHROSCOPY; ARTICLE; CATABOLISM; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; IN VITRO STUDY; JOINT BIOPSY; MALE; MIDDLE AGED; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOSARCOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; RHEUMATOID ARTHRITIS; SYNOVIUM; WESTERN BLOTTING; X RAY; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; OSTEOLYSIS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; BONE RESORPTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNOVIAL MEMBRANE;

EID: 84888780824     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4398     Document Type: Article

References (21)

1. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009, 373:659-672. 10.1016/S0140-6736(09)60008-8, 19157532.
2. Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 2005, 1:47-54. 10.1038/ncprheum0036, 16932627.
3. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004, 50:36-42. 10.1002/art.11481, 14730597.
4. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008, 58:2958-2967. 10.1002/art.23945, 18821687.
5. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681. 10.1016/S0140-6736(04)15640-7, 15001324, TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators.
6. Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 2007, 9:R61. 10.1186/ar2219, 2206336, 17597527.
7. Catrina AI, af Klint E, Ernestam S, Catrina SB, Makrygiannakis D, Botusan IR, Klareskog L, Ulfgren AK. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 2006, 54:76-81. 10.1002/art.21528, 16385498.
8. Makrygiannakis D, af Klint E, Catrina SB, Botusan IR, Klareskog E, Klareskog L, Ulfgren AK, Catrina AI. Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. Arthritis Rheum 2006, 54:1463-1472. 10.1002/art.21767, 16646024.
9. Suematsu A, Tajiri Y, Nakashima T, Taka J, Ochi S, Oda H, Nakamura K, Tanaka S, Takayanagi H. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. Mod Rheumatol 2007, 17:17-23. 10.1007/s10165-006-0531-1, 17278017.
10. Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon HB. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum 2004, 50:3831-3843. 10.1002/art.20637, 15593184.
11. Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Herrmann M, Smolen J, Schett G. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 2008, 67:1603-1609. 10.1136/ard.2007.080713, 18203760.
12. Axmann R, Bohm C, Kronke G, Zwerina J, Smolen J, Schett G. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 2009, 60:2747-2756. 10.1002/art.24781, 19714627.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
14. van Tuyl LH, Voskuyl AE, Boers M, Geusens P, Landewe RB, Dijkmans BA, Lems WF. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis 2010, 69:1623-1628. 10.1136/ard.2009.121764, 20525836.
15. Bologna C, Edno L, Anaya JM, Canovas F, Vanden Berghe M, Jorgensen C, Galtier M, Combe B, Bressolle F, Sany J. Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum 1994, 37:1770-1773. 10.1002/art.1780371210, 7986223.
16. Meesters RJ, den Boer E, de Jonge R, Lindemans J, Luider TM. Assessment of intracellular methotrexate and methotrexate-polyglutamate metabolite concentrations in erythrocytes by ultrafast matrix-assisted laser desorption/ionization triple quadrupole tandem mass spectrometry. Rapid Commun Mass Spectrom 2011, 25:3063-3070. 10.1002/rcm.5202, 21953961.
17. Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986, 29:832-835. 10.1002/art.1780290703, 2427090.
18. Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 1995, 22:38-40.
19. Ralph JA, McEvoy AN, Kane D, Bresnihan B, FitzGerald O, Murphy EP. Modulation of orphan nuclear receptor NURR1 expression by methotrexate in human inflammatory joint disease involves adenosine A2A receptor-mediated responses. J Immunol 2005, 175:555-565.
20. Majumdar S, Aggarwal BB. Methotrexate suppresses NF-κB activation through inhibition of IκBα phosphorylation and degradation. J Immunol 2001, 167:2911-2920.
21. Soysa NS, Alles N. NF-κB functions in osteoclasts. Biochem Biophys Res Commun 2009, 378:1-5. 10.1016/j.bbrc.2008.10.146, 18992710.